Page last updated: 2024-10-27

fluorouracil and Dermatitis Medicamentosa

fluorouracil has been researched along with Dermatitis Medicamentosa in 121 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment."9.20Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015)
"This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients."9.14Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009)
"We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel."9.13Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008)
"We describe a 47-year-old man who developed a linear serpentine erythematous eruption, overlying the superficial veins on both arms, after treatment with intravenous 5-fluorouracil."8.80Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. ( Alomar, A; Lopez-Pousa, A; Pujol, RM; Rocamora, V; Taberner, R, 1998)
"This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC)."7.80Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. ( Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S, 2014)
"A 42-year-old woman being treated with 5-fluorouracil for carcinoma of the sigmoid colon developed persistent serpentine supravenous hyperpigmented eruption (PSSHE), bilateral mottling of the palms and diffuse hyperpigmentation of the soles."7.805-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. ( Agrawal, A; Parihar, A; Suvirya, S, 2014)
"It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan."7.74Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. ( Adachi, A; Horikawa, T; Nagai, H, 2007)
"The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy."7.69Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997)
"Fluorouracil is a common cause of acral erythema and a variety of pigmentary anomalies."7.68Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. ( Beard, JS; Skelton, HG; Smith, KJ, 1993)
" We should pay attention to the dosage of 5-FU and ActD, monitor adverse reactions strictly, to reduce occurrence of skin malignant events."6.825-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review. ( Li, T; Liu, Y; Wang, M; Wang, S; Wang, Y; Zhang, L; Zhang, X, 2022)
"The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible."6.73A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008)
"Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2."6.45[Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009)
"5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses."5.62Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021)
"A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment."5.20Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015)
"This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients."5.14Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009)
"We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel."5.13Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008)
"We report on a 63-year-old female patient with breast cancer treated with epirubicin combination therapy."4.90Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature. ( Aigner, B; Arzberger, EJ; Bauernhofer, T; Niederkorn, A; Petru, E; Richtig, E, 2014)
"We describe a 47-year-old man who developed a linear serpentine erythematous eruption, overlying the superficial veins on both arms, after treatment with intravenous 5-fluorouracil."4.80Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. ( Alomar, A; Lopez-Pousa, A; Pujol, RM; Rocamora, V; Taberner, R, 1998)
"This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC)."3.80Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. ( Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S, 2014)
"A 42-year-old woman being treated with 5-fluorouracil for carcinoma of the sigmoid colon developed persistent serpentine supravenous hyperpigmented eruption (PSSHE), bilateral mottling of the palms and diffuse hyperpigmentation of the soles."3.805-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. ( Agrawal, A; Parihar, A; Suvirya, S, 2014)
" They had osteosarcoma in methotrexate group (n=7), gastrointestinal malignancies in 5FU group (n=9) and breast cancer in the capecitabine group (n=2)."3.78Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. ( Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B, 2012)
"It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan."3.74Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. ( Adachi, A; Horikawa, T; Nagai, H, 2007)
"The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy."3.69Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997)
"Fluorouracil is a common cause of acral erythema and a variety of pigmentary anomalies."3.68Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. ( Beard, JS; Skelton, HG; Smith, KJ, 1993)
" Skin toxicity outcomes were collected using the Common Toxicity Criteria for Adverse Events version 3."3.01Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). ( Alberts, SR; Banbury, BL; Chan, AT; Cohen, SA; George, TJ; Goldberg, RM; Harrison, TA; Hua, X; Huyghe, JR; Labadie, JD; Newcomb, PA; Penney, KL; Peters, U; Phipps, AI; Shi, Q; Sinicrope, FA; Sun, W; Yothers, G, 2021)
"Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al."2.84Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017)
" We should pay attention to the dosage of 5-FU and ActD, monitor adverse reactions strictly, to reduce occurrence of skin malignant events."2.825-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review. ( Li, T; Liu, Y; Wang, M; Wang, S; Wang, Y; Zhang, L; Zhang, X, 2022)
"Erlotinib can be safely administered with adjuvant IMRT-based CRT and chemotherapy."2.78Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. ( Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L, 2013)
"The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible."2.73A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008)
"Fluorouracil alone can cause a variety of dermatologic adverse effects; however, it is not considered to be a chemical vesicant."2.67Local tissue reaction to intravenous fluorouracil and leucovorin. ( Decker, DA; Fryer, NL; Umstead, GS, 1991)
"Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2."2.45[Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009)
"In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) the estimated prognosis is usually poor."1.62Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. ( Amorim, C; Domingues, I; Felix, R; Garcia, AR; João Sousa, M; Mariano, M; Pontes, F; Salgueiro, F; Teixeira, M, 2021)
"5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses."1.62Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021)
"5 fluorouracil therapy was terminated and the patients were shifted to interferon therapy subsequently."1.51Severe necrotising inflammatory skin reaction to topical 5-fluorouracil. ( Gokhale, NS, 2019)
"Close monitoring and prompt discontinuation of the drugs with high volume of distribution and metabolized through the liver are necessary to avoid drug-drug interaction in liver transplant patients."1.40Liver injury possibly related to drug interaction after liver transplant: a case report. ( Jiang, WT; Liu, YH; Pan, C; Thian, Y; Zhu, LQ, 2014)
"The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life."1.39Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013)
"Necrolytic migratory erythema is an obligatory paraneoplastic syndrome."1.39Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. ( Enk, AH; Gronau, M; Hassel, JC; Jäger, D, 2013)
"Twenty-one patients with inoperable colon cancer in the pelvis were treated with intra-arterial 5-fluorouracil (5-FU) and mitomycin C, given bilaterally into the internal iliac arteries."1.27Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. ( Chuang, VP; Claghorn, L; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1985)
"Among 26 colorectal cancer patients assessable for response there was a 15."1.26Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981)

Research

Studies (121)

TimeframeStudies, this research(%)All Research%
pre-199034 (28.10)18.7374
1990's18 (14.88)18.2507
2000's36 (29.75)29.6817
2010's27 (22.31)24.3611
2020's6 (4.96)2.80

Authors

AuthorsStudies
Wang, S3
Li, T3
Wang, Y3
Wang, M3
Liu, Y3
Zhang, X3
Zhang, L3
Soueidy, C1
Skaff, S1
Stephan, F1
Kattan, J1
Gokhale, NS1
Labadie, JD1
Hua, X1
Harrison, TA1
Banbury, BL1
Huyghe, JR1
Sun, W1
Shi, Q1
Yothers, G1
Alberts, SR1
Sinicrope, FA1
Goldberg, RM1
George, TJ1
Penney, KL1
Phipps, AI1
Cohen, SA1
Peters, U1
Chan, AT1
Newcomb, PA1
Pontes, F1
Garcia, AR1
Domingues, I1
João Sousa, M1
Felix, R1
Amorim, C1
Salgueiro, F1
Mariano, M1
Teixeira, M1
Béguin, J1
Kohlhauer, M1
Laloy, E1
Degorce, F1
Moreau, B1
Quéméneur, É1
Erbs, P1
Klonjkowski, B1
Maurey, C1
Yi, JZ1
Himes, RS1
Smith, RJ2
McKee, PH1
Roberts, AA1
Matsuda, K1
Namiki, T1
Ueno, M1
Hashimoto, T1
Hanafusa, T1
Yokozeki, H1
Hernandez-Aragues, I1
Baniandrés-Rodríguez, O1
Avilés-Izquierdo, JA1
Vilas-Boas, PT1
Nemer, KM1
Solus, JF1
Schaffer, A1
Rosman, IS1
Lee, SJ1
Haas, M1
Siveke, JT1
Schenk, M1
Lerch, MM1
Caca, K1
Freiberg-Richter, J1
Fischer von Weikersthal, L1
Kullmann, F1
Reinacher-Schick, A1
Fuchs, M1
Kanzler, S1
Kunzmann, V1
Ettrich, TJ1
Kruger, S1
Westphalen, CB1
Held, S1
Heinemann, V1
Boeck, S1
Neal, DE1
Aberbigbe, O1
Etzkorn, JR1
Senda, N1
Miyagaki, T1
Oka, T1
Nonogaki, A1
Yoshizaki, A1
Shibata, S1
Sato, S1
Herman, JM1
Fan, KY1
Wild, AT1
Hacker-Prietz, A1
Wood, LD1
Blackford, AL1
Ellsworth, S1
Zheng, L1
Le, DT1
De Jesus-Acosta, A1
Hidalgo, M1
Donehower, RC1
Schulick, RD1
Edil, BH1
Choti, MA1
Hruban, RH1
Pawlik, TM1
Cameron, JL1
Laheru, DA1
Wolfgang, CL1
Doyen, J1
Benezery, K1
Follana, P1
Ortholan, C1
Gérard, JP1
Hannoun-Levi, JM1
Gal, J1
Francois, E1
Zhu, LQ1
Jiang, WT1
Pan, C1
Liu, YH1
Thian, Y1
Taieb, J1
Tabernero, J1
Mini, E1
Subtil, F1
Folprecht, G1
Van Laethem, JL1
Thaler, J1
Bridgewater, J1
Petersen, LN1
Blons, H1
Collette, L1
Van Cutsem, E1
Rougier, P2
Salazar, R1
Bedenne, L1
Emile, JF1
Laurent-Puig, P1
Lepage, C1
Walker, G1
Lane, N1
Parekh, P1
Araki, K1
Fukada, I1
Horii, R1
Takahashi, S1
Akiyama, F1
Iwase, T1
Ito, Y1
Suvirya, S1
Agrawal, A1
Parihar, A1
Aigner, B1
Bauernhofer, T1
Petru, E1
Niederkorn, A1
Arzberger, EJ1
Richtig, E2
Tian, J1
Shang, M1
Shi, SB1
Han, Y1
Xu, J1
Imran, F1
Harman, K1
Pomerantz, H1
Korgavkar, K1
Lee, KC1
Lew, R1
Weinstock, MA1
Fattouh, K1
Collet-Benzaquen, D1
Provensal, AM1
Desseigne, F1
Castillo, C1
Combemale, P1
de la Fouchardière, A1
Schimanski, CC1
Staib, F1
Göhler, T1
Hebart, H1
Heike, M1
Neise, M1
Rudi, J1
Geer, T1
Dingeldein, G1
Lang, C1
Ehscheidt, P1
Flohr, T1
Josten, KM1
Karthaus, M1
Schmittel, A1
Wierecky, J1
Boller, E1
Indorf, M1
Wörns, MA1
Galle, PR1
Moehler, M1
Piqué-Duran, E1
Pérez-Díaz, MJ1
Pérez-Cejudo, JA1
Susnjar, S1
Bosnjak, SM1
Radulovic, S1
Bajetta, E1
Di Bartolomeo, M1
Buzzoni, R1
Ferrario, E1
Dotti, KF1
Mariani, L1
Bajetta, R1
Gevorgyan, A1
Venturino, P1
Galassi, M1
Floristan, U1
Feltes, RA1
Sendagorta, E1
Feito-Rodriguez, M1
Ramírez-Marín, P1
Vidaurrázaga, C1
Casado-Jiménez, M1
Gutiérrez-Pascual, M1
Sols-Candela, M1
Pinedo, F1
López-Estebaranz, JL1
Pikó, B1
Black, JM1
Hodari, KT1
Rogers, N1
Farris, PK1
Lewis, AT1
Boh, EE1
Partl, R1
Kapp, KS1
Powers, R1
Gordon, R1
Roberts, K1
Kovach, R1
Kim, MY1
Kang, SY1
Lee, SY1
Yang, MS1
Kim, MH1
Song, WJ1
Kim, SH1
Kim, YJ1
Lee, KW1
Cho, SH1
Min, KU1
Lee, JS1
Kim, JH1
Chang, YS1
Dogan, M1
Karabulut, HG1
Tukun, A1
Demirkazik, A1
Utkan, G1
Yalcin, B1
Dincol, D1
Akbulut, H1
Icli, F1
Sargen, M1
Wanat, KA1
Jambusaria, A1
Rosenbach, M1
Sobanko, J1
Miller, CJ1
Gronau, M1
Jäger, D1
Enk, AH1
Hassel, JC1
Bogenrieder, T1
Weitzel, C1
Schölmerich, J1
Landthaler, M1
Stolz, W1
Wetzig, T1
Beckheinrich, P1
Rytter, M1
Haustein, UF1
Piguet, V1
Borradori, L1
Kirkup, ME1
Narayan, S1
Kennedy, CT1
Bocci, G1
Danesi, R1
Allegrini, G1
Innocenti, F1
Di Paolo, A1
Falcone, A1
Conte, PF1
Del Tacca, M1
Chen, GY1
Chang, TW1
Chen, WC1
Eiseman, AS1
Flanagan, JC1
Brooks, AB1
Mitchell, EP1
Pemberton, CH1
Risum, S1
Langer, SW1
ROSSMAN, RE1
KNOX, JM1
FREEMAN, RG1
LANE, M1
MOERTEL, CG2
REITEMEIER, RJ2
HAHN, RG2
HURLEY, JD1
ANSFIELD, FJ1
MCCAFFERY, JF1
Childress, J1
Lokich, J1
Arikawa, R1
Kanekura, T1
Uchimiya, H1
Kanzaki, T1
Labandeira, J1
Pereiro, M1
Valdés, F1
Toribio, J1
Sorscher, SM1
Fukushima, S1
Hatta, N1
Merk, HF1
Wilkes, GM1
Doyle, D1
Abdel-Wahab, M1
Abitbol, A1
Lewin, A1
Troner, M1
Hamilton, K1
Markoe, A1
Lee, A1
Ezzeldin, H1
Fourie, J1
Diasio, R1
Woodruff, CA1
Amrikachi, M1
Hsu, S1
Laing, ME1
Laing, TA1
Mulligan, NJ1
Keane, FM1
Gugerli, O1
Leupin, N1
Hague, JS1
Ilchyshyn, A1
Sroa, N1
Bartholomew, DA1
Magro, CM1
Adachi, A1
Nagai, H1
Horikawa, T1
Addeo, R1
Montella, L1
Baldi, A1
Cennamo, G1
Guarrasi, R1
Faiola, V1
Caraglia, M1
Del Prete, S1
Tol, J1
Koopman, M1
Rodenburg, CJ1
Cats, A1
Creemers, GJ1
Schrama, JG1
Erdkamp, FL1
Vos, AH1
Mol, L1
Antonini, NF1
Punt, CJ1
Saif, MW1
Seller, S1
Diasio, RB1
Di Fiore, F1
Karlin, DA1
Stroehlein, JR1
Nixon, DW1
Pirozzi, D1
York, RM1
Black, M1
Lawson, DH1
Epstein, E2
Presant, CA2
Ardalan, B2
Multhauf, P1
Chan, C1
Staples, R1
Green, L1
Browning, S1
Carr, BI1
Chang, FF1
Thayer, W1
Legha, SS1
Ajani, JA2
Blumenschein, GR1
Hortobagyi, GN1
Buzdar, AU1
Jamin, D1
Jayaram, HN1
Reed, WP1
Morris, DM1
Singer, Z1
Kozaczka, A1
Wilk, J1
Janas, J1
Herrmann, R1
Spehn, J1
Beyer, JH1
von Franqué, U1
Schmieder, A1
Holzmann, K1
Abel, U1
Galentine, P1
Sloas, H1
Hargett, N1
Cupples, HP1
Fox, RM1
Woods, RL1
Tattersall, MH1
Piper, AA1
Sampson, D1
Hann, SK1
Rhoe, BS1
Kang, WH1
Park, YK1
Kingsley, EC1
Beard, JS1
Smith, KJ1
Skelton, HG1
Prussick, R1
Thibault, A1
Turner, ML1
Nadal, C1
Pujol, RM2
Randazzo, L1
Marcuello, E1
Alomar, A2
Anderson, LL1
Welch, ML1
Grabski, WJ1
Chiara, S1
Nobile, MT1
Barzacchi, C1
Sanguineti, O1
Vincenti, M1
Di Somma, C1
Meszaros, P1
Rosso, R1
Rocamora, V1
Lopez-Pousa, A1
Taberner, R1
von Moos, R1
Sauter, C1
Sánchez-Pérez, J1
Bartolomé, B1
del Río, MJ1
García-Díez, A1
Schaefer, U1
Micke, O1
Schueller, P1
Willich, N1
Wang, HM1
Ng, SH1
Wang, CH1
Liaw, CT1
Chen, JS1
Yang, TS1
Chen, IH1
Lubowe, II1
Bernstein, T1
Schlang, HA1
Curtin, R1
Cullen, SI1
de Berker, D1
Marren, P1
Powell, SM1
Ryan, TJ1
Umstead, GS1
Fryer, NL1
Decker, DA1
Grunberg, SM1
Clay, C1
Spicer, DV1
Jordá, E1
Galan, A1
Betlloch, I1
Ramon, D1
Revert, A1
Torres, V1
Vukelja, SJ1
Bonner, MW1
McCollough, M1
Cobb, PW1
Gaule, DA1
Fanucchi, PJ1
Keeling, JH1
Blackburn, WD1
Alarcón, GS1
Obrist, R1
Haenggi, ST1
Heiman, D1
Obrecht, JP1
Grattan, CE1
Guerrier, CJ1
Feldman, LD1
Schosser, RH1
Tennstedt, D1
Lachapelle, JM1
Shelley, WB1
Shelley, ED1
Guillaume, JC1
Carp, E1
Charpentier, P1
André, P1
Carde, P1
Avril, MF1
Patt, YZ1
Peters, RE1
Chuang, VP1
Wallace, S1
Claghorn, L1
Mavligit, G1
Caballero, GA1
Ausman, RK1
Quebbeman, EJ1
Giai, M1
De Fabiani, E1
Lamberto, A1
Cortese, P1
Giardina, G1
Levantine, A1
Almeyda, J1
Goldmann, L1
Igelman, JM1
Kitzmiller, K1
Sams, WM1
Farah, FS1
Shbaklo, Z1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274]Phase 33,397 participants (Actual)Interventional2004-02-29Completed
Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances[NCT01729481]Phase 2150 participants (Actual)Interventional2012-07-31Active, not recruiting
Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer[NCT00313560]Phase 248 participants (Actual)Interventional2006-03-16Completed
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694]Phase 349 participants (Actual)Interventional2019-05-11Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.)
Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811]Phase 32,559 participants (Actual)Interventional2005-11-30Completed
Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab[NCT03362684]Phase 31,808 participants (Actual)Interventional2005-11-30Completed
Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)[NCT02364024]856 participants (Actual)Observational2005-11-30Completed
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912]Phase 4954 participants (Actual)Interventional2009-06-26Completed
The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034]14 participants (Actual)Interventional2020-08-04Terminated (stopped due to Principal Investigator retired before study completed.)
Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study[NCT00208546]Phase 3750 participants (Actual)Interventional2005-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Disease-free Survival (Arms A and D: Mutant KRAS Patients)

"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A67.1
Mutant KRAS Arm D65.0

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A74.6
Wild-type KRAS Arm D71.5

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A87.9
Mutant KRAS Arm D82.7

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A87.3
Wild-type KRAS Arm D85.6

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Mutant KRAS Arm A55.6
Mutant KRAS Arm D72.3

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Wild-type KRAS Arm A51.1
Wild-type KRAS Arm D73.3

Recurrence Free Survival

Time from surgery to recurrence (NCT00313560)
Timeframe: Up to 3 years

Interventionmonths (Median)
Erlotinib and EBRT After Pancreatectomy15.6

Time to Death as Assessed by Median Overall Survival (Months)

(NCT00313560)
Timeframe: up to 5 years

Interventionmonths (Median)
Erlotinib and EBRT After Pancreatectomy24.39

Change in QoL as Assessed by QLQ-PAN 26

Quality of life (QOL) was assessed before CRT was started or during the first week of its administration (baseline [BL]), between completion of CRT and starting maintenance chemotherapy (time 1 [t1]), and within 3 months after completion of maintenance chemotherapy (time 2 [t2]). QLQ-PAN 26 questionnaire includes 26 questions, organized into 7 scales, with scores for each ranging from 0-100. Higher scores indicate worse health state. Therefore, decreasing (negative) scores indicate a better outcome. (NCT00313560)
Timeframe: 3 months

Interventionscore on a scale (Mean)
Pancreatic Pain (t1 vs. BL)Pancreatic Pain (t2 vs. BL)Pancreatic Pain (t2 vs. t1)Digestive (t1 vs. BL)Digestive (t2 vs. BL)Digestive (t2 vs. t1)Altered Bowel Habits (t1 vs. BL)Altered Bowel Habits (t2 vs. BL)Altered Bowel Habits (t2 vs. t1)Jaundice (t1 vs. BL)Jaundice (t2 vs. BL)Jaundice (t2 vs. t1)Body Image (t1 vs. BL)Body Image (t2 vs. BL)Body Image (t2 vs. t1)Satisfaction with healthcare (t1 vs. BL)Satisfaction with health care (t2 vs. BL)Satisfaction with health care (t2 vs. t1)Sexual function (t1 vs. BL)Sexual function (t2 vs. BL)Sexual function (t2 vs. t1)
Erlotinib and EBRT After Pancreatectomy-1.9-3.82.4-0.9-4.6-1.414.77.2-4.9-1.3-20-6.2-3.1-0.74.13.10-0.514.714.1

Change in Quality of Life (QoL) as Assessed by EORTC QLQ-C30 (Version 3.0)

Quality of life (QOL) was assessed before chemoradiation therapy (CRT) was started or during the first week of its administration [baseline (BL)], between completion of CRT and starting maintenance chemotherapy [time 1 (t1)], and within 3 months after completion of maintenance chemotherapy [time 2 (t2)]. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses quality of life on three domains: symptoms (score ranges from 7-14); function (score range 21-82); and global health status (score range 2-14). Higher or increasing scores mean worse outcomes; lower or decreasing scores mean better outcomes. (NCT00313560)
Timeframe: Up to 3 months after completion of maintenance chemotherapy

Interventionscore on a scale (Mean)
Global (Time 1 vs. BL)Global (Time 2 vs. BL)Global (Time 2 vs. Time 1)Functional (F) - Physical (Time 1 vs. BL)F - Physical (Time 2 vs. BL)F - Physical (Time 2 vs. Time 1)F - Role (Time 1 vs. BL)F - Role (Time 2 vs. BL)F - Role (Time 2 vs. Time 1)F - Cognition (Time 1 vs. BL)F - Cognition (Time 2 vs. BL)F - Cognition (Time 2 vs. Time 1)F - Emotional (Time 1 vs. BL)F - Emotional (Time 2 vs. BL)F - Emotional (Time 2 vs. Time 1)F - Social (Time 1 vs. BL)F - Social (Time 2 vs. BL)F - Social (Time 2 vs. Time 1)Financial (Time 1 vs. BL)Financial (Time 2 vs. BL)Financial (Time 2 vs. Time 1)General Symptoms (GS) - Fatigue (Time 1 vs. BL)GS - Fatigue (Time 2 vs. BL)GS - Fatigue (Time 2 vs. Time 1)GS - Nausea/Vomiting (Time 1 vs. BL)GS - Nausea/Vomiting (Time 2 vs. BL)GS - Nausea/Vomiting (Time 2 vs. Time 1)GS - Pain (Time 1 vs. BL)GS - Pain (Time 2 vs. BL)GS - Pain (Time 2 vs. Time 1)GS - Dyspnea (Time 1 vs. BL)GS - Dyspnea Time 2 vs. BL)GS - Dyspnea (Time 2 vs. Time 1)GS - Insomnia (Time 1 vs. BL)GS - Insomnia (Time 2 vs. BL)GS - Insomnia (Time 2 vs. Time 1)GS - Appetite Loss (Time 1 vs. BL)GS - Appetite Loss (Time 2 vs. BL)GS - Appetite Loss (Time 2 vs. Time 1)GS - Constipation (Time 1 vs. BL)GS - Constipation (Time 2 vs. BL)GS - Constipation (Time 2 vs. Time 1)GS - Diarrhea (Time 1 vs. BL)GS - Diarrhea (Time 2 vs. BL)GS - Diarrhea (Time 2 vs. Time 1)
Erlotinib and EBRT After Pancreatectomy1-1.84.60.5-3.2-6.2-3.1-0.3-4.4-2.61.2-1.2-0.42.2-0.63.94.4-3.81.72.505.75.21.72.501.92.77.251.73.81.2-2.502.5-2.5-15-5-4.2-2.5014.78.8-6.2

Number of Participants Experiencing Adverse Events

Number of participants experiencing adverse events during chemoradiation and during adjuvant chemotherapy, Grade 2 or higher, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. This is used to determine the Toxicity profile. (NCT00313560)
Timeframe: up to 3 years

,
InterventionParticipants (Count of Participants)
Grade 2Grade 3Grade 4
Adjuvant Gemcitabine Plus Erlotinib15143
Chemoradiation Plus Erlotinib24151

Hazard Ratio for Surgically Treated KC

(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years

Interventionparticipants (Number)
Arm 1: 5-fluorouracil182
Arm 2: Placebo, Vehicle Control177

The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed

Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years

Interventionyears (Median)
Arm 1: 5-fluorouracil3.37
Arm 2: Placebo, Vehicle Control3.52

Reviews

13 reviews available for fluorouracil and Dermatitis Medicamentosa

ArticleYear
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole,

2022
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole,

2022
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole,

2022
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole,

2022
Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
    Dermatology (Basel, Switzerland), 2014, Volume: 229, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexrazoxane; Dim

2014
[Toxic dermatitis due to capecitabine: presentation of 2 cases and literature review].
    Actas dermo-sifiliograficas, 2009, Volume: 100, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Fluorouracil; Hu

2009
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
    Magyar onkologia, 2009, Volume: 53, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2009
Systemic toxicity from occlusive therapy with topical 5-fluorouracil: a case report and review of the literature.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2012, Volume: 38, Issue:10

    Topics: Abdominal Pain; Administration, Cutaneous; Antimetabolites, Antineoplastic; Chills; Diarrhea; Drug E

2012
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
    The British journal of dermatology, 2003, Volume: 148, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine

2003
[Pharmacogenetics: Important aspects for dermatology].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2005, Volume: 56, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Dapsone; Dermatology; Drug Eruptions; Fluorou

2005
Palmar-plantar erythrodysesthesia.
    Clinical journal of oncology nursing, 2005, Volume: 9, Issue:1

    Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Doxorubicin; Drug Eruptions; Erythema; Fem

2005
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:8

    Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di

2004
Lipodermatosclerosis as a form of vascular compromise-associated radiation recall dermatitis: case report and a review of literature.
    Journal of cutaneous pathology, 2006, Volume: 33 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin;

2006
Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy.
    Journal of the American Academy of Dermatology, 1998, Volume: 39, Issue:5 Pt 2

    Topics: Antimetabolites, Antineoplastic; Dermis; Drug Eruptions; Erythema; Fluorouracil; Follow-Up Studies;

1998
Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil.
    Journal of the American Academy of Dermatology, 1991, Volume: 25, Issue:5 Pt 2

    Topics: Adenocarcinoma; Aged; Drug Eruptions; Fluorouracil; Humans; Infusions, Intravenous; Male; Photosensi

1991
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
    The British journal of dermatology, 1974, Volume: 90, Issue:2

    Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor

1974

Trials

13 trials available for fluorouracil and Dermatitis Medicamentosa

ArticleYear
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021, Volume: 30, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Drug Eruptions; Female

2021
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 94

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycyti

2018
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemot

2013
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; C

2015
Validation of Photograph-Based Toxicity Score for Topical 5-Fluorouracil Cream Application.
    Journal of cutaneous medicine and surgery, 2016, Volume: 20, Issue:5

    Topics: Administration, Cutaneous; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous C

2016
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:6

    Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant

2017
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008, Volume: 16, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-

2008
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud

2009
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su

2005
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2008
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2001
Local tissue reaction to intravenous fluorouracil and leucovorin.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Fluorouracil; Humans; Infusions, Int

1991

Other Studies

95 other studies available for fluorouracil and Dermatitis Medicamentosa

ArticleYear
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
    Anti-cancer drugs, 2023, 01-01, Volume: 34, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu

2023
Severe necrotising inflammatory skin reaction to topical 5-fluorouracil.
    Indian journal of ophthalmology, 2019, Volume: 67, Issue:12

    Topics: Administration, Ophthalmic; Antimetabolites, Antineoplastic; Conjunctival Neoplasms; Drug Eruptions;

2019
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Cancer treatment and research communications, 2021, Volume: 27

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Drug

2021
Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.
    BMC veterinary research, 2021, Jun-21, Volume: 17, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Drug Eruptions; Drug-Relat

2021
Painful scrotal dermatitis secondary to topical 5-fluorouracil.
    Dermatology online journal, 2021, Jun-15, Volume: 27, Issue:6

    Topics: Administration, Topical; Aged; Drug Eruptions; Fluorouracil; Humans; Keratosis, Actinic; Male; Pain;

2021
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
    European journal of dermatology : EJD, 2017, 06-01, Volume: 27, Issue:3

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop

2017
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient.
    European journal of dermatology : EJD, 2017, Jun-01, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2017
Generalized pustular drug eruption caused by topical 5-fluorouracil.
    Dermatologic therapy, 2017, Volume: 30, Issue:5

    Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Female; Fluorourac

2017
Cells to Surgery Quiz: July 2018.
    The Journal of investigative dermatology, 2018, Volume: 138, Issue:7

    Topics: Administration, Cutaneous; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Diseas

2018
Case of purpuric drug eruption probably induced by panitumumab.
    The Journal of dermatology, 2019, Volume: 46, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Colonic Neoplasms; Drug Erupti

2019
Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
    Diseases of the colon and rectum, 2013, Volume: 56, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac

2013
Liver injury possibly related to drug interaction after liver transplant: a case report.
    Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:4

    Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Chemical and Drug Induced Live

2014
Photosensitive lichenoid drug eruption to capecitabine.
    Journal of the American Academy of Dermatology, 2014, Volume: 71, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Female; Fluorour

2014
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
    Breast cancer research and treatment, 2014, Volume: 148, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy

2014
5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles.
    BMJ case reports, 2014, Oct-21, Volume: 2014

    Topics: Adult; Antimetabolites, Antineoplastic; Antioxidants; Biopsy; Clobetasol; Diagnosis, Differential; D

2014
A perplexing case.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:5

    Topics: Aged, 80 and over; Drug Eruptions; Fluorouracil; Genital Diseases, Male; Groin; Humans; Male; Skin U

2016
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
    The American Journal of dermatopathology, 2017, Volume: 39, Issue:10

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorecta

2017
Pyogenic granuloma-like lesions caused by capecitabine therapy.
    Clinical and experimental dermatology, 2008, Volume: 33, Issue:5

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Eruptions; Fingers; Fl

2008
Subacute cutaneous lupus erythematosus induced by capecitabine.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Erupt

2009
Exudative, nonhealing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab.
    Archives of dermatology, 2011, Volume: 147, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
Calling attention to radiation recall reactions. Simultaneous occurrence of a Recall Dermatitis after CMF application in two separate sites irradiated 10 years apart.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph

2012
Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil.
    Cutis, 2012, Volume: 89, Issue:5

    Topics: Administration, Cutaneous; Drug Eruptions; Exanthema; Fluorouracil; Hand Dermatoses; Humans; Immunos

2012
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:4

    Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycy

2012
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineop

2012
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neur

2013
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
    Dermatology (Basel, Switzerland), 2002, Volume: 205, Issue:2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms

2002
Erosion of psoriatic plaques: an uncommon side-effect of neoadjuvant 5-fluorouracil treatment of colon cancer.
    The British journal of dermatology, 2002, Volume: 147, Issue:4

    Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Eruptions; Fluorouracil

2002
Pyogenic granuloma-like lesions during capecitabine therapy.
    The British journal of dermatology, 2002, Volume: 147, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Fluorouracil; Fo

2002
Cutaneous recall reactions with systemic fluorouracil.
    Dermatology (Basel, Switzerland), 2003, Volume: 206, Issue:2

    Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Esophageal Neoplasms

2003
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
    European journal of clinical pharmacology, 2002, Volume: 58, Issue:9

    Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever

2002
Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil.
    Ophthalmic plastic and reconstructive surgery, 2003, Volume: 19, Issue:3

    Topics: Adult; Antimetabolites, Antineoplastic; Black or African American; Cohort Studies; Drug Eruptions; E

2003
[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Ugeskrift for laeger, 2003, Aug-11, Volume: 165, Issue:33

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response R

2003
CLINICOPATHOLOGIC CONFERENCE.
    Texas state journal of medicine, 1964, Volume: 60

    Topics: Black People; Bromides; Diagnosis, Differential; Drug Eruptions; Fluorouracil; Granuloma; Humans; Ke

1964
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
    Gastroenterology, 1964, Volume: 46

    Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human

1964
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko

1964
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
    JAMA, 1964, Nov-16, Volume: 190

    Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid

1964
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
    The Medical journal of Australia, 1964, Oct-10, Volume: 2

    Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo

1964
Cutaneous hand and foot toxicity associated with cancer chemotherapy.
    American journal of clinical oncology, 2003, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Docetaxel; Doxorubicin; Drug Eruptions; Erythema; Fluorouracil; Foot; Hand; H

2003
A case of prurigo-type drug eruptions due to UFT.
    The Journal of dermatology, 2003, Volume: 30, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Drug Eruptions; Fe

2003
Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:4 Pt 1

    Topics: Administration, Topical; Adult; Aged; Drug Administration Schedule; Drug Eruptions; Fluorouracil; Hu

2004
Penile involvement with hand-foot syndrome.
    American journal of clinical dermatology, 2004, Volume: 5, Issue:3

    Topics: Antineoplastic Agents; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male;

2004
Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug.
    The British journal of dermatology, 2004, Volume: 151, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Drug Eruptions; Fluorouracil; Humans

2004
Zosteriform metastatic transitional cell carcinoma.
    International journal of dermatology, 2005, Volume: 44, Issue:12

    Topics: Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Transitional

2005
Eosinophilic pustular folliculitis induced by chemotherapy.
    Journal of the American Academy of Dermatology, 2006, Volume: 54, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Eruptions;

2006
[Blisters unlike others].
    Revue medicale suisse, 2006, Apr-19, Volume: 2, Issue:62

    Topics: Aged; Antimetabolites, Antineoplastic; Blister; Capecitabine; Deoxycytidine; Drug Eruptions; Female;

2006
Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer.
    Clinical and experimental dermatology, 2007, Volume: 32, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Eruptions

2007
Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions.
    Dermatology (Basel, Switzerland), 2007, Volume: 214, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Autoantibodies; Biopsy; Diagnosis, Differential; Drug Eruptio

2007
Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eruptions; Fluorouraci

2007
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
    JOP : Journal of the pancreas, 2008, Mar-08, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; D

2008
[Non-resectable metastases from colorectal cancers].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:5 Pt 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2008
Rash, nephritis, hypertension, and haemolysis in patient on 5-fluorouracil, doxorubicin, and mitomycin-C.
    Lancet (London, England), 1980, Sep-06, Volume: 2, Issue:8193

    Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Doxorubicin; Drug Eruptions; Drug Therapy, Combinati

1980
Dermatologic changes after systemic cancer therapy.
    Cutis, 1981, Volume: 27, Issue:2

    Topics: Adult; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Cytotoxins; Dactinomycin; Doxorubicin; Dr

1981
Hidden fluorouracil applications as a cause of dermatitis and erosions.
    JAMA, 1983, Mar-25, Volume: 249, Issue:12

    Topics: Administration, Topical; Aged; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Male

1983
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
    Medical and pediatric oncology, 1983, Volume: 11, Issue:3

    Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio

1983
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
    Cancer, 1984, May-01, Volume: 53, Issue:9

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms;

1984
Phase I study of continuous-infusion PALA and 5-FU.
    Cancer treatment reports, 1984, Volume: 68, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti

1984
Maculopapular eruption resulting from systemic administration of 5-fluorouracil.
    Cutis, 1984, Volume: 33, Issue:4

    Topics: Aged; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans

1984
[Non-hematologic adverse effects of cytostatic drugs].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1984, Nov-19, Volume: 39, Issue:47

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female;

1984
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug

1984
Bilateral cicatricial ectropion following topical administration of 5-fluorouracil.
    Annals of ophthalmology, 1981, Volume: 13, Issue:5

    Topics: Administration, Topical; Aged; Cicatrix; Drug Eruptions; Ectropion; Facial Dermatoses; Fluorouracil;

1981
Allopurinol modulation of fluorouracil toxicity.
    Cancer chemotherapy and pharmacology, 1981, Volume: 5, Issue:3

    Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans;

1981
Self limited dermal invasion of keratinocytes in maculopapular eruptions after systemic chemotherapy.
    The Journal of dermatology, 1993, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Breast Neoplasms; Carcinoma, Intr

1993
5-Fluorouracil dermatitis prophylaxis with a nicotine patch.
    Annals of internal medicine, 1994, May-01, Volume: 120, Issue:9

    Topics: Administration, Cutaneous; Aged; Drug Eruptions; Female; Fluorouracil; Humans; Nicotine

1994
Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease.
    Journal of the American Academy of Dermatology, 1993, Volume: 29, Issue:2 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Erythema; Female; Fluorouracil; Graf

1993
Recall of cutaneous toxicity from fluorouracil.
    Archives of dermatology, 1993, Volume: 129, Issue:5

    Topics: Adult; Drug Eruptions; Fluorouracil; Humans; Immunologic Memory; Male

1993
Systemic contact dermatitis from 5-fluorouracil.
    Contact dermatitis, 1996, Volume: 35, Issue:2

    Topics: Antimetabolites, Antineoplastic; Dermatitis, Allergic Contact; Drug Eruptions; Fluorouracil; Humans;

1996
Allergic contact dermatitis and reactivation phenomenon from iontophoresis of 5-fluorouracil.
    Journal of the American Academy of Dermatology, 1997, Volume: 36, Issue:3 Pt 1

    Topics: Aged; Antimetabolites, Antineoplastic; Dermatitis, Allergic Contact; Drug Eruptions; Fluorouracil; H

1997
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:6

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1997
Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation?
    Journal of the American Academy of Dermatology, 1998, Volume: 38, Issue:1

    Topics: Administration, Cutaneous; Antimetabolites; Dermatitis; Drug Administration Schedule; Drug Eruptions

1998
[Photosensitization caused by 5-fluorouracil (5-FU)].
    Schweizerische medizinische Wochenschrift, 1999, Jan-12, Volume: 129, Issue:1-2

    Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Diagnosis, Differential; Drug Eruptions; F

1999
Allergic contact dermatitis from 5-fluorouracil with positive intradermal test and doubtful patch test reactions.
    Contact dermatitis, 1999, Volume: 41, Issue:2

    Topics: Dermatitis, Allergic Contact; Drug Eruptions; Female; Fluorouracil; Humans; Immunosuppressive Agents

1999
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
    Radiology, 2000, Volume: 216, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2000
Cutaneous drug reaction case reports: from the world literature.
    American journal of clinical dermatology, 2002, Volume: 3, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Capecitabine; Carbamates; Ceftriaxone; Clonidine; Deoxyc

2002
Fluorouracil for skin blemishes and lines.
    JAMA, 1977, Mar-28, Volume: 237, Issue:13

    Topics: Dermatitis, Contact; Drug Eruptions; Fluorouracil; Humans

1977
Skin reactions to 5-fluorouracil.
    The New England journal of medicine, 1977, Aug-11, Volume: 297, Issue:6

    Topics: Breast Neoplasms; Drug Eruptions; Drug Hypersensitivity; Female; Fluorouracil; Humans; Injections, I

1977
Inflammation of malignant skin involvement with fluorouracil.
    JAMA, 1977, Oct-17, Volume: 238, Issue:16

    Topics: Breast Neoplasms; Drug Eruptions; Female; Fluorouracil; Humans; Middle Aged

1977
Topical fluorouracil therapy for precancers and cancers of the skin.
    Journal of the American Geriatrics Society, 1979, Volume: 27, Issue:12

    Topics: Administration, Topical; Drug Eruptions; Fluorouracil; Humans; Keratosis; Precancerous Conditions; S

1979
Contact sensitivity to the stearyl alcohol in Efudix cream (5-fluorouracil).
    Contact dermatitis, 1992, Volume: 26, Issue:2

    Topics: Aged; Dermatitis, Contact; Drug Eruptions; Fatty Alcohols; Female; Fluorouracil; Humans; Keratosis

1992
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
    Selective cancer therapeutics, 1991,Spring, Volume: 7, Issue:1

    Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans;

1991
Painful, red hands. A side effect of 5-fluorouracil by continuous perfusion.
    International journal of dermatology, 1991, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans; Mi

1991
Toxic response to topical fluorouracil in two rheumatoid arthritis patients receiving low-dose, weekly methotrexate.
    Arthritis and rheumatism, 1990, Volume: 33, Issue:2

    Topics: Aged; Arthritis, Rheumatoid; Drug Eruptions; Drug Synergism; Fluorouracil; Humans; Keratosis; Male;

1990
Localized skin toxicity from 5-fluorouracil after paravenous infusion of leukovorin calcium.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:5

    Topics: Drug Eruptions; Fluorouracil; Humans; Injections, Subcutaneous; Leucovorin; Liver Neoplasms; Male; M

1990
Reaction to topical fluorouracil of secondary lymphedema.
    Archives of dermatology, 1985, Volume: 121, Issue:12

    Topics: Aged; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Lymphedema; Ointments

1985
Fluorouracil-associated dermatitis of the hands and feet.
    JAMA, 1985, Dec-27, Volume: 254, Issue:24

    Topics: Adult; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male

1985
Toxic reaction to prolonged high-dose fluorouracil.
    JAMA, 1986, Jun-13, Volume: 255, Issue:22

    Topics: Drug Eruptions; Fluorouracil; Humans

1986
Allergic contact dermatitis to 5-fluorouracil.
    Contact dermatitis, 1987, Volume: 16, Issue:5

    Topics: Adult; Drug Eruptions; Fluorouracil; Humans; Male; Skin Diseases; Warts

1987
Scrotal dermatitis caused by 5-fluorouracil (Efudex).
    Journal of the American Academy of Dermatology, 1988, Volume: 19, Issue:5 Pt 2

    Topics: Adolescent; Adult; Condylomata Acuminata; Dermatitis, Contact; Drug Eruptions; Fluorouracil; Genital

1988
[Cutaneomucous adverse effects of continuous infusion of 5-fluorouracil: 12 cases].
    Annales de dermatologie et de venereologie, 1988, Volume: 115, Issue:11

    Topics: Adult; Drug Eruptions; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Infusions, In

1988
Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin.
    Cancer, 1985, Nov-01, Volume: 56, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C

1985
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil

1985
[Secondary effects of adjuvant therapy].
    Minerva ginecologica, 1985, Volume: 37, Issue:6

    Topics: Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha

1985
Investigative studies with DMSO in dermatology.
    Annals of the New York Academy of Sciences, 1967, Mar-15, Volume: 141, Issue:1

    Topics: Animals; Dermatomycoses; Dimethyl Sulfoxide; Drug Eruptions; Fluocinolone Acetonide; Fluorouracil; G

1967
Untoward response with topical fluorouracil.
    Archives of dermatology, 1968, Volume: 97, Issue:1

    Topics: Aged; Carcinoma, Basal Cell; Drug Eruptions; Female; Fluorouracil; Humans; Keratosis; Male; Middle A

1968
Combination chemotherapy in gastrointestinal cancer.
    Cancer research, 1970, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall

1970
The treatment of premalignant and malignant skin lesions with 5-fluorouracil.
    Le Journal medical libanais. The Lebanese medical journal, 1971, Volume: 24, Issue:1

    Topics: Drug Eruptions; Female; Fluorouracil; Humans; Keratosis; Male; Precancerous Conditions; Skin; Skin N

1971